scholarly journals Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways

2013 ◽  
Vol 29 (4) ◽  
pp. 1563-1569 ◽  
Author(s):  
LI-JUAN WANG ◽  
SU-XIA HAN ◽  
E BAI ◽  
XIA ZHOU ◽  
MENG LI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Signaling Pathways ◽  
Breast Cancer Cells ◽  
Akt Signaling ◽  
Dependent Effect ◽  
Tamoxifen Resistant ◽  
Dose Dependent ◽  
Dose Dependent Effect

Biphasic Dose-Dependent Effect of Lithium Chloride on Survival of Human Hormone-Dependent Breast Cancer Cells (MCF-7)

2012 ◽  
Vol 150 (1-3) ◽  
pp. 477-486 ◽  
Author(s):  
Muralidharan Suganthi ◽  
Gopalakrishnan Sangeetha ◽  
Govindaraj Gayathri ◽  
Bhaskaran Ravi Sankar
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Lithium Chloride ◽  
Breast Cancer Cells ◽  
Dependent Effect ◽  
Dose Dependent ◽  
Dose Dependent Effect ◽  
Mcf 7

Verrucarin A induces apoptosis through ROS-mediated EGFR/MAPK/Akt signaling pathways in MDA-MB-231 breast cancer cells

2014 ◽  
pp. n/a-n/a ◽  
Author(s):  
Kandasamy Palanivel ◽  
Veerasamy Kanimozhi ◽  
Balamuthu Kadalmani ◽  
Mohammad Abdulkader Akbarsha
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Signaling Pathways ◽  
Breast Cancer Cells ◽  
Akt Signaling

scholarly journals Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways

2010 ◽  
Vol 126 (2) ◽  
pp. 545-562 ◽  
Author(s):  
Sandra E. Ghayad ◽  
Julie A. Vendrell ◽  
Sabrina Ben Larbi ◽  
Charles Dumontet ◽  
Ivan Bieche ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Signaling Pathways ◽  
Breast Cancer Cells ◽  
Endocrine Resistance ◽  
Akt Signaling

scholarly journals IL-1β Promotes Vasculogenic Mimicry of Breast Cancer Cells Through p38/MAPK and PI3K/Akt Signaling Pathways

2021 ◽  
Vol 11 ◽  
Author(s):  
Muhammad Azhar Nisar ◽  
Qin Zheng ◽  
Muhammad Zubair Saleem ◽  
Bulbul Ahmmed ◽  
Muhammad Noman Ramzan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Signaling Pathways ◽  
P38 Mapk ◽  
Breast Cancer Cells ◽  
Vasculogenic Mimicry ◽  
Akt Signaling ◽  
Immunofluorescent Staining ◽  
Morphological Evidence ◽  
Mcf 7

Vasculogenic mimicry (VM), a micro vessel-like structure formed by the cancer cells, plays a pivotal role in cancer malignancy and progression. Interleukin-1 beta (IL-1β) is an active pro-inflammatory cytokine and elevated in many tumor types, including breast cancer. However, the effect of IL-1β on the VM of breast cancer has not been clearly elucidated. In this study, breast cancer cells (MCF-7 and MDA-MB-231) were used to study the effect of IL-1β on the changes that can promote VM. The evidence for VM stimulated by IL-1β was acquired by analyzing the expression of VM-associated biomarkers (VE-cadherin, VEGFR-1, MMP-9, MMP-2, c-Fos, and c-Jun) via western blot, immunofluorescent staining, and Immunohistochemistry (IHC). Additionally, morphological evidence was collected via Matrigel-based cord formation assay under normoxic/hypoxic conditions and microvessel examination through Hematoxylin and Eosin staining (H&E). Furthermore, the STRING and Gene Ontology database was also used to analyze the VM-associated interacting molecules stimulated by IL-β. The results showed that the expression of VM biomarkers was increased in both MCF-7 and MDA-MB-231 cells after IL-1β treatment. The increase in VM response was observed in IL-1β treated cells under both normoxia and hypoxia. IL-1β also increased the activation of transcription factor AP-1 complex (c-Fos/c-Jun). The bioinformatics data indicated that p38/MAPK and PI3K/Akt signaling pathways were involved in the IL-1β stimulation. It was further confirmed by the downregulated expression of VM biomarkers and reduced formation of the intersections upon the addition of the signaling pathway inhibitors. The study suggests that IL-1β stimulates the VM and its associated events in breast cancer cells via p38/MAPK and PI3K/Akt signaling pathways. Aiming the VM-associated molecular targets promoted by IL-1β may offer a novel anti-angiogenic therapeutic strategy to control the aggressiveness of breast cancer cells.

Sign in / Sign up

Export Citation Format

Share Document